3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 3
2
Phase NA
1
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Carcinoma, Non-Small-Cell Lung
44
Lung Neoplasms
13
Pancreatic Neoplasms
5
Non-Squamous Non-Small Cell Lung Cancer
5
Neoplasms
4
Colorectal Neoplasms
3
Thoracic Neoplasms
2
Respiratory Tract Diseases
2
Neoplasm Metastasis
2
Carcinoma
2
Brain Neoplasms
2
Stage IV EGFR Mutated Non-Small Cell Lung Cancer
1
Solid Tumor
1
Respiratory Tract Neoplasms
1
Rectal Neoplasms
1
Pancreatic Intraductal Neoplasms
1
Ovarian Neoplasms
1
Non-squamous Non-small Cell Lung Cancer
1
Non - Small Cell Lung Cancer NSCLC
1
Neoplasms by Site
1
NSCLC
1
Mouth Neoplasms
1
Lung Diseases
1
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
1
Head and Neck Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Ovarian Epithelial
1
Interventions
Carboplatin
17
Cisplatin
14
Paclitaxel
12
Pemetrexed
11
pembrolizumab
9
Gemcitabine
7
Docetaxel
6
Sorafenib
5
osimertinib
4
durvalumab
4
130-nm albumin-bound paclitaxel
4
padeliporfin
3
cabozantinib
3
atezolizumab
3
Taxes
3
Radiotherapy
3
Mitomycin
3
Magnetic Resonance Spectroscopy
3
Cetuximab
3
Bevacizumab
3
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
3
trifluridine tipiracil drug combination
2
regorafenib
2
olaparib
2
Sunitinib
2
Specimen Handling
2
Radiotherapy, Intensity-Modulated
2
Radiation
2
Nivolumab
2
Irinotecan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Carcinoma
×
Erlotinib Hydrochloride
×
Clear all
NCT02134015
2018-01-23
HER3-Lung
Daiichi Sankyo
Phase 3
Terminated
145 enrolled
20 charts
NCT00673049
2013-07-24
NSCLC
Pfizer
Phase 3
Terminated
583 enrolled
11 charts